{"id":41594,"date":"2022-05-11T13:02:25","date_gmt":"2022-05-11T07:32:25","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=41594"},"modified":"2022-05-11T13:02:30","modified_gmt":"2022-05-11T07:32:30","slug":"shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/","title":{"rendered":"Shares of Aurobindo Pharma Slip to 52 week low after US FDA issues Form 483"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-631138497\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>The shares of&nbsp; Aurobindo Pharma have hit a fresh 52 week low of \u20b9580.10 after dropping 3.81% on the bourses.&nbsp;&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3282322068\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>&nbsp;The United States Food and Drug Administration (US FDA) inspected its manufacturing facility at Jedcherla, Hyderabad from May 2 to 10 and issued a Form 483 with six observations. The pharma major said that It will respond to the US FDA within the stipulated timeline and work closely with the US FDA to close the observations.<\/p><p>Form 483 is issued to notify the management of the company about objectionable conditions observed by its officials that may constitute violations of the Food Drug and Cosmetic Act and related Acts.<\/p><p>Earlier this month, Aurobindo Pharma\u2019s wholly-owned subsidiary, Eugia Pharma had received approval from the US health regulator to market the anti-cancer medication Bortezomib for injection. This product is a generic equivalent of Takeda Pharmaceuticals&#8217; Velcade for injection. <\/p><div class=\"trade-content_5\" id=\"trade-538860321\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>The shares of the company were quoting at \u20b9 600.00 levels at 11:30 am on Wednesday, lower by 0.65% on the NSE.\u00a0\u00a0<\/p><p><strong>Disclaimer<\/strong><\/p><div class=\"wp-block-image\"><figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer.png\" alt=\"\" class=\"wp-image-26306\" width=\"256\" height=\"256\"\/><\/figure><\/div><p><strong>The content in this news article is not investment advice. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-1143975988\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>The shares of&nbsp; Aurobindo Pharma have hit a fresh 52 week low of \u20b9580.10 after dropping 3.81% on the bourses.&nbsp;&nbsp; &nbsp;The United States Food and Drug Administration (US FDA) inspected its manufacturing facility at Jedcherla, Hyderabad from May 2 to 10 and issued a Form 483 with six observations. The pharma major said that It [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":41598,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[3485,1734,3484,948,2573,936,3483],"class_list":["post-41594","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-52-week-low-stocks","tag-aurobindo-pharma","tag-stock-52-week-low","tag-stock-market","tag-stock-market-crash","tag-stock-market-news","tag-stocks-at-52-week-low"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Shares of Aurobindo Pharma Slip to 52 week low after US FDA issues Form 483 - Trade Brains Features<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shares of Aurobindo Pharma Slip to 52 week low after US FDA issues Form 483\" \/>\n<meta property=\"og:description\" content=\"The shares of&nbsp; Aurobindo Pharma have hit a fresh 52 week low of \u20b9580.10 after dropping 3.81% on the bourses.&nbsp;&nbsp; &nbsp;The United States Food and Drug Administration (US FDA) inspected its manufacturing facility at Jedcherla, Hyderabad from May 2 to 10 and issued a Form 483 with six observations. The pharma major said that It [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-11T07:32:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-11T07:32:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/05\/Aurobindo-Pharma-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/\",\"url\":\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/\",\"name\":\"Shares of Aurobindo Pharma Slip to 52 week low after US FDA issues Form 483 - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/05\/Aurobindo-Pharma-Cover-Image.jpg\",\"datePublished\":\"2022-05-11T07:32:25+00:00\",\"dateModified\":\"2022-05-11T07:32:30+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/05\/Aurobindo-Pharma-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/05\/Aurobindo-Pharma-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shares of Aurobindo Pharma Slip to 52 week low after US FDA issues Form 483\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shares of Aurobindo Pharma Slip to 52 week low after US FDA issues Form 483 - Trade Brains Features","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/","og_locale":"en_US","og_type":"article","og_title":"Shares of Aurobindo Pharma Slip to 52 week low after US FDA issues Form 483","og_description":"The shares of&nbsp; Aurobindo Pharma have hit a fresh 52 week low of \u20b9580.10 after dropping 3.81% on the bourses.&nbsp;&nbsp; &nbsp;The United States Food and Drug Administration (US FDA) inspected its manufacturing facility at Jedcherla, Hyderabad from May 2 to 10 and issued a Form 483 with six observations. The pharma major said that It [&hellip;]","og_url":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2022-05-11T07:32:25+00:00","article_modified_time":"2022-05-11T07:32:30+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/05\/Aurobindo-Pharma-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/","url":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/","name":"Shares of Aurobindo Pharma Slip to 52 week low after US FDA issues Form 483 - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/05\/Aurobindo-Pharma-Cover-Image.jpg","datePublished":"2022-05-11T07:32:25+00:00","dateModified":"2022-05-11T07:32:30+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/05\/Aurobindo-Pharma-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/05\/Aurobindo-Pharma-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/shares-of-aurobindo-pharma-slip-to-52-week-low-after-us-fda-issues-form-483\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Shares of Aurobindo Pharma Slip to 52 week low after US FDA issues Form 483"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/41594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=41594"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/41594\/revisions"}],"predecessor-version":[{"id":41600,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/41594\/revisions\/41600"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/41598"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=41594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=41594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=41594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}